Analysis of an HIV-infected cohort followed for as long as 15 years after seroconversion

Aspectos psicossociais na era dos novos tratamentos da AIDS

O presente artigo descreve o impacto no bem-estar (ansiedade e depressão) e qualidade de vida das pessoas HIV+ quando o tratamento anti-retroviral não apresenta os resultados esperados. Foram avaliadas, através de questionários, as percepções e expectativas com o tratamento anti-retroviral, o nível de ansiedade e depressão, o nível de apoio social e a qualidade de vida percebida em 80 pacientes HIV+ em atendimento em um hospital universitário. Os resultados indicaram que as percepções e expectativas negativas com o tratamento podem modular o estado emocional e impactar negativamente a qualidade de vida das pessoas HIV+; e que um nível de apoio social adequado é capaz de atenuar este impacto negativo.

Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team

BACKGROUND

Neuropsychological testing and 2 measures of neurological status, cortical atrophy, and motor dysfunction were assessed for their usefulness in predicting human immunodeficiency virus (HIV) disease progression in infants, children, and adolescents who participated in Pediatric AIDS Clinical Trials Group Protocol 152 (PACTG 152).

METHODS

A cohort of 722 antiretroviral therapy-naive children with symptomatic HIV infection were assessed at study entry and at later intervals. Assessments included neurodevelopmental testing, neuroradiologic imaging, and neurological examination of motor function. CD4 cell count and plasma RNA viral load also were measured.

RESULTS

Children with the lowest neuropsychological functioning (IQ < 70) at baseline had the highest risk for later HIV disease progression (56%), compared with those with borderline/low (IQ = 70-89) functioning (26%), or with average or above (IQ > 90) functioning (18%). This was also true of week 48 neuropsychological functioning. Motor dysfunction (especially reduced muscle mass) at entry also predicted disease progression. Furthermore, motor dysfunction and week 48 neuropsychological functioning provided predictive information beyond that obtainable from surrogate markers of HIV disease status (eg, CD4 count, HIV RNA level). Children with cortical atrophy also were at higher risk for later disease progression, but when CD4 count and RNA viral load were known, cortical atrophy information provided no additional predictive information.

CONCLUSIONS

Measures of neuropsychological and motor function status provide unique information regarding pediatric HIV disease progression. As such, these findings have important implications for predicting long-term outcomes (eg, longevity) in pediatric patients.